Fanny Piette

5.0k total citations · 3 hit papers
24 papers, 3.4k citations indexed

About

Fanny Piette is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Fanny Piette has authored 24 papers receiving a total of 3.4k indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 9 papers in Cancer Research and 7 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Fanny Piette's work include Breast Cancer Treatment Studies (8 papers), HER2/EGFR in Cancer Research (7 papers) and Advanced Breast Cancer Therapies (3 papers). Fanny Piette is often cited by papers focused on Breast Cancer Treatment Studies (8 papers), HER2/EGFR in Cancer Research (7 papers) and Advanced Breast Cancer Therapies (3 papers). Fanny Piette collaborates with scholars based in Belgium, United States and France. Fanny Piette's co-authors include Christos Sotiriou, Martine Piccart, Sherene Loi, Giuseppe Viale, Marc Buyse, Fátima Cardoso, Angelo Di Leo, Adrian L. Harris, Rosette Lidereau and Peter Ellis and has published in prestigious journals such as Journal of Clinical Oncology, The Journal of Immunology and JNCI Journal of the National Cancer Institute.

In The Last Decade

Fanny Piette

23 papers receiving 3.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Prognostic and Predictive Value of Tumor-Infiltrating Lymphocytes in a Phase III Randomized Adjuvant Breast Cancer Trial in Node-Positive Breast Cancer Comparing the Addition of Docetaxel to Doxorubicin With Doxorubicin-Based Chemotherapy: BIG 02-98

2013 1.2k citations Sherene Loi, Nicolas Sirtaine et al. Journal of Clinical Oncology profile →
Validation and Clinical Utility of a 70-Gene Prognostic Signature for Women With Node-Negative Breast Cancer

2006 842 citations Marc Buyse, Sherene Loi et al. JNCI Journal of the National Cancer Institute profile →
Strong Time Dependence of the 76-Gene Prognostic Signature for Node-Negative Breast Cancer Patients in the TRANSBIG Multicenter Independent Validation Series

2007 726 citations Christine Desmedt, Fanny Piette et al. Clinical Cancer Research profile →

Peers

Countries citing papers authored by Fanny Piette

Since Specialization

Citations

This map shows the geographic impact of Fanny Piette's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fanny Piette with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fanny Piette more than expected).

Fields of papers citing papers by Fanny Piette

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Fanny Piette. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fanny Piette. The network helps show where Fanny Piette may publish in the future.

Co-authorship network of co-authors of Fanny Piette

This figure shows the co-authorship network connecting the top 25 collaborators of Fanny Piette. A scholar is included among the top collaborators of Fanny Piette based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Fanny Piette. Fanny Piette is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Safety and Efficacy of T-DM1 Plus Neratinib in Patients With Metastatic HER2-Positive Breast Cancer: NSABP Foundation Trial FB-10 2019 ·Journal of Clinical Oncology ·Jame Abraham, (unknown), Rachel C. Jankowitz, Mohamad A. Salkeni, Jan H. Beumer, Brian F. Kiesel, Fanny Piette, (unknown), Rebecca J. Nagy, Richard B. Lanman, Jeff Sperinde, Weidong Huang, Carmen J. Allegra, Ashok Srinivasan, Ying Wang, Katherine L. Pogue–Geile, Peter C. Lucas, Samuel A. Jacobs	59
2	Study protocol for THINK: a multinational open-label phase I study to assess the safety and clinical activity of multiple administrations of NKR-2 in patients with different metastatic tumour types 2017 ·BMJ Open ·Caroline Lonez, Bikash Verma, Alain Hendlisz, Philippe Aftimos, Ahmad Awada, Eric Van Den Neste, (unknown), Jean‐Pascal Machiels, Fanny Piette, Jason Brayer, David A. Sallman, Tessa Kerre, Kunle Odunsi, Marco L. Davila, David E. Gilham, Frédéric Lehmann	42
3	Prognostic and Predictive Value of Tumor-Infiltrating Lymphocytes in a Phase III Randomized Adjuvant Breast Cancer Trial in Node-Positive Breast Cancer Comparing the Addition of Docetaxel to Doxorubicin With Doxorubicin-Based Chemotherapy: BIG 02-98 breakdown → 2013 ·Journal of Clinical Oncology ·Sherene Loi, Nicolas Sirtaine, Fanny Piette, Roberto Salgado, Giuseppe Viale, (unknown), Ghizlane Rouas, Prudence A. Francis, John Crown, Erika Hitre, Evandro de Azambuja, Emmanuel Quinaux, Angelo Di Leo, Stefan Michiels, Martine Piccart, Christos Sotiriou	1213
4	Correlation Between Quantitative HER-2 Protein Expression and Risk for Brain Metastases in HER-2+ Advanced Breast Cancer Patients Receiving Trastuzumab-Containing Therapy 2012 ·The Oncologist ·Renata Duchnowska, Wojciech Biernat, Barbara Szostakiewicz, Jeff Sperinde, Fanny Piette, Mojgan Haddad, Agnès Paquet, (unknown), Bogumiła Czartoryska-Arłukowicz, Piotr J. Wysocki, (unknown), Barbara Radecka, Małgorzata Foszczyńska‐Kłoda, Maria Litwiniuk, (unknown), Jodi Weidler, Weidong Huang, Marc Buyse, Michael Bates, Jacek Jassem	27
5	Concurrent Bevacizumab with a Sequential Regimen of Doxorubicin and Cyclophosphamide Followed by Docetaxel and Capecitabine as Neoadjuvant Therapy for HER2− Locally Advanced Breast Cancer: A Phase II Trial of the NSABP Foundation Research Group 2011 ·Clinical Breast Cancer ·Priya Rastogi, Marc Buyse, Sandra M. Swain, Samuel A. Jacobs, André Robidoux, Marcia K. Liepman, Eduardo R. Pajon, (unknown), Juan G. Posada, Marianne K. Melnik, Fanny Piette, Charles E. Geyer, E.P. Mamounas, Norman Wolmark	13
6	Evaluation of the prognostic and predictive value of tumor-infiltrating lymphocytes (TILs) in a phase III randomized adjuvant breast cancer (BC) trial (BIG 2-98) of node-positive (N+) BC comparing the addition of docetaxel to doxorubicin (A-T) with doxorubicin (A)-only chemotherapy (CT). 2011 ·Journal of Clinical Oncology ·Sherene Loi, Rodrigo Salgado, Fanny Piette, Nicolas Sirtaine, (unknown), Roswitha Kammler, G. Rouas, Prudence A. Francis, John Crown, Bo Nordenskjöld, (unknown), Magnus Andersson, Mireia Margelí Vila, R. Jakesz, (unknown), Emmanuel Quinaux, Angelo Di Leo, Stefan Michiels, (unknown), Martine Piccart	5
7	Quantitation of HER2 Expression or HER2:HER2 Dimers and Differential Survival in a Cohort of Metastatic Breast Cancer Patients Carefully Selected for Trastuzumab Treatment Primarily by FISH 2009 ·Diagnostic Molecular Pathology ·Christine Desmedt, Jeff Sperinde, Fanny Piette, Weidong Huang, Xueguang Jin, (unknown), Virginie Durbecq, Denis Larsimont, Rosa Giuliani, Colombe Chappey, Marc Buyse, John Winslow, Martine Piccart, Christos Sotiriou, Christos J. Petropoulos, Michael Bates	31
8	A meta-analysis of phase III trials evaluating the predictive value of HER2 and topoisomerase II alpha in early breast cancer patients treated with CMF or anthracycline-based adjuvant therapy. 2009 ·Cancer Research ·Angelo Di Leo, J Isola, Fanny Piette, Bent Ejlertsen, Kathleen I. Pritchard, (unknown), Christine Desmedt, Denis Larsimont, Minna Tanner, Henning T. Mouridsen, (unknown), C.J. Twelves, Fátima Cardoso, C. J. Poole, M. Piccart, (unknown)	42
9	Comparison of prognostic gene expression signatures for breast cancer 2008 ·BMC Genomics ·Benjamin Haibe‐Kains, Christine Desmedt, Fanny Piette, Marc Buyse, Fátima Cardoso, Laura van’t Veer, Martine Piccart, Gianluca Bontempi, Christos Sotiriou	100
10	Strong Time Dependence of the 76-Gene Prognostic Signature for Node-Negative Breast Cancer Patients in the TRANSBIG Multicenter Independent Validation Series breakdown → 2007 ·Clinical Cancer Research ·Christine Desmedt, Fanny Piette, Sherene Loi, Yixin Wang, Françoise Lallemand, Benjamin Haibe‐Kains, Giuseppe Viale, Mauro Delorenzi, Yi Zhang, (unknown), Jonas Bergh, Rosette Lidereau, Peter Ellis, Adrian L. Harris, Jan G.M. Klijn, John A. Foekens, Fátima Cardoso, Martine Piccart, Marc Buyse, Christos Sotiriou	726
11	Paraneoplastic pemphigus with pemphigus vegetans-like lesions revealing non-Hodgkin lymphoma. 2007 ·PubMed ·(unknown), (unknown), D. Gilbert, Fanny Piette, E. Delaporte	7
12	Destructive Cleavage of Antigenic Peptides Either by the Immunoproteasome or by the Standard Proteasome Results in Differential Antigen Presentation 2006 ·The Journal of Immunology ·Jacques Chapiro, Stéphane Claverol, Fanny Piette, Wenbin Ma, Vincent Stroobant, Benoît Guillaume, (unknown), Sandra Morel, Odile Burlet‐Schiltz, Bernard Monsarrat, Thierry Boon, Benoı̂t J. Van den Eynde	125
13	Validation and Clinical Utility of a 70-Gene Prognostic Signature for Women With Node-Negative Breast Cancer breakdown → 2006 ·JNCI Journal of the National Cancer Institute ·Marc Buyse, Sherene Loi, Laura van’t Veer, Giuseppe Viale, Mauro Delorenzi, Annuska M. Glas, (unknown), Jonas Bergh, Rosette Lidereau, Peter Ellis, Adrian L. Harris, Jan Bogaerts, Patrick Therasse, Arno Floore, (unknown), Fanny Piette, Emiel J. Rutgers, Christos Sotiriou, Fátima Cardoso, Martine Piccart	842
14	Unrelated Donor Status and High Donor Age Independently Affect Immunologic Recovery after Nonmyeloablative Conditioning 2006 ·Biology of Blood and Marrow Transplantation ·Frédéric Baron, Barry E. Storer, Michael B. Maris, Jan Storek, Fanny Piette, (unknown), Kristen White, Brenda M. Sandmaier, David G. Maloney, Rainer Storb, Michael Boeckh	45
15	Juvenile Xanthogranuloma: A Congenital Giant Form Leading to a Wide Atrophic Sequela 2004 ·Pediatric Dermatology ·(unknown), O. Carpentier, (unknown), Elisabeth Martin de Lassalle, Fanny Piette	12
16	Blau syndrome of granulomatous arthritis, iritis, and skin rash: A new family and review of the literature 1998 ·American Journal of Medical Genetics ·Sylvie Manouvrier‐Hanu, Bernard Puech, Fanny Piette, (unknown), (unknown), B Duquesnoy, (unknown)	61
17	A New Case of Isolated Trichothiodystrophy 1993 ·Dermatology ·S. Alfandari, Éric Delaporte, D. Van Neste, (unknown), Fanny Piette, H Bergoend	13
18	[Pemphigus vulgaris induced by radiotherapy]. 1991 ·PubMed ·E. Delaporte, Fanny Piette, H Bergoend	14
19	[Laser in dermatology: biological effects; indications (author's transl)]. 1981 ·PubMed ·(unknown), Fanny Piette, (unknown), (unknown), H Bergoend	1
20	[Multiple reticulo-histiocytoma]. 1980 ·PubMed ·Fanny Piette, (unknown), (unknown), H Bergoend	11

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact